Children formula food for promoting skeletal muscle development

Abstract

The invention provides a children formula food for promoting skeletal muscle development, which comprises lactoferrin and pyrroloquinoline quinone disodium salt in a weight ratio of (20: 1)-(30: 1). The children formula food has the effect of promoting skeletal muscle development, ensures that children can fully absorb and utilize the key nutrients, and remarkably improves muscle quality, muscle strength and muscle functions.

Description

Technical Field

[0001] The invention relates to the technical field of functional compositions, and in particular to a pediatric formula food for promoting skeletal muscle development. Background Art

[0002] Skeletal muscle is usually attached to bones and distributed in the head, neck, trunk and limbs. It performs the functions of relaxation and contraction in the body. Skeletal muscle accounts for about 40% of the body weight of mammals and is the largest tissue organ in non-obese people. Growth and development are the most basic characteristics of children's life process, including cell proliferation and differentiation to make various organs, systems and bodies grow and mature. As an important part of the body, skeletal muscle plays an important role in maintaining the normal growth and development of children. The degree of development of children's muscles is closely related to age. In mature individuals, the number of muscle cells remains unchanged. In the first few years after birth, muscle development is slow. After the age of 4, muscle growth is obvious, muscle cell volume increases, myofibrils and sarcomeres increase, myofibrils become thicker and longer, mitochondria and other organelles and stored glycogen increase, connective tissue and capillaries in skeletal muscle also increase, muscles bulge, and muscle accounts for an increased percentage of body mass. Studies have shown that maintaining good skeletal muscle growth and development in childhood is not only beneficial to the development of children's motor skills and nervous system development, but also has a beneficial effect on diseases such as cardiovascular health in adulthood.

[0003] Lactoferrin is an iron-binding glycoprotein widely found in mammalian milk. It is the core immune protein in breast milk and has multiple biological activities, including antiviral infection, anti-oxidation, anti-bacterial, anti-cancer, anti-inflammatory and immunomodulatory. Studies have shown that lactoferrin promotes osteoblast proliferation and differentiation and inhibits osteoclasts, playing an important role in children's bone development.

[0004] Pyrroloquinoline quinone disodium salt (PQQ) is widely present in nature and is abundant in breast milk, ranging from 140-180ng / mL. PQQ is considered a strong antioxidant that has the functions of maintaining mitochondrial function, regulating the body's free radical levels, inhibiting inflammatory responses, and protecting and promoting bone and joint health. Studies have shown that PQQ prevents osteoporosis caused by testosterone deficiency by stimulating osteoblast bone formation and inhibiting osteoclast bone resorption.

[0005] At present, there are no reports on the effects of lactoferrin and pyrroloquinoline quinone disodium salt (PQQ) on promoting skeletal muscle development after combined use. Therefore, further research and discussion on the specific relationship between them is of great significance. Summary of the invention

[0006] In order to solve the above technical problems, the purpose of the present invention is to provide a pediatric formula food that promotes skeletal muscle development, which can promote bone and development, improve and enhance muscle quality, muscle strength and muscle function.

[0007] To achieve the above object, the present invention first provides a pediatric formula food, which contains a composition of lactoferrin and pyrroloquinoline quinone disodium salt, wherein the weight ratio of lactoferrin to pyrroloquinoline quinone disodium salt is 20:1-30:1.

[0008] The present invention also provides an application of a composition in the preparation of a product for promoting bone and development, wherein the composition contains lactoferrin and pyrroloquinoline quinone disodium salt, and the weight ratio of lactoferrin to pyrroloquinoline quinone disodium salt is 20:1-30:1. Specifically, the product is an edible product, which can be a medicine or food (ordinary food, health food, special medical food, therapeutic diet, etc.). Preferably, the product is a pediatric formula food.

[0009] In the above-mentioned pediatric formula food, preferably, the weight ratio of lactoferrin to pyrroloquinoline quinone disodium salt is 22:1-28:1, more preferably 25:1.

[0010] In the above-mentioned pediatric formula food, preferably, based on the mass of the pediatric formula food, the added amount of lactoferrin is 30-360 mg / 100 g, and the added amount of pyrroloquinoline quinone disodium salt is 1.5-12 mg / 100 g.

[0011] In the above-mentioned pediatric formula food, preferably, the purity of the pyrroloquinoline quinone disodium salt is ≥98.0 g / 100 g, calculated on a dry basis.

[0012] In the above-mentioned pediatric formula food, preferably, the pediatric formula food is powdered pediatric formula food, powdered children's reconstituted milk powder or pediatric formula liquid milk.

[0013] In the above-mentioned pediatric formula food, more preferably, based on the preparation of 1000 weight parts of the powdered pediatric formula food, the raw material composition of the powdered pediatric formula food includes: 0-7000 weight parts of raw cow's milk, 0-600 weight parts of desalted whey powder, 0-500 weight parts of lactose, 0-500 weight parts of skim milk powder, 0-400 weight parts of edible vegetable blending oil, 0-100 weight parts of prebiotics, 0-120 weight parts of whey protein powder, 0-20 weight parts of phospholipids, 0-20 weight parts of vitamins, 0-40 weight parts of casein, and 0-30 weight parts of minerals.

[0014] In the above-mentioned pediatric formula food, more preferably, based on the preparation of 1000 weight parts of the powdered children's formula milk powder, the raw material composition of the powdered children's formula milk powder includes: 0-7000 weight parts of raw cow's milk, 0-500 weight parts of skim milk powder, 0-600 weight parts of desalted whey powder, 0-120 weight parts of whey protein powder, 0-500 weight parts of lactose, 0-50 weight parts of prebiotics, 0-5 weight parts of choline, 0-10 weight parts of phospholipids, 0-20 weight parts of vitamins, and 0-30 weight parts of minerals.

[0015] In the above-mentioned pediatric formula food, more preferably, based on the preparation of 1000 parts by weight of the pediatric formula liquid milk, the raw material composition of the pediatric formula liquid milk includes: 0-7000 parts by weight of raw cow's milk, 0-500 parts by weight of skim milk powder, 0-500 parts by weight of desalted whey powder, 0-500 parts by weight of lactose, 0-400 parts by weight of edible vegetable blending oil, 0-100 parts by weight of prebiotics, 0-120 parts by weight of whey protein powder, 0-10 parts by weight of phospholipids, 0-40 parts by weight of casein, 0-20 parts by weight of vitamins, and 0-30 parts by weight of minerals.

[0016] In the above-mentioned pediatric formula food, it is further preferred that the raw cow's milk is partially skimmed milk.

[0017] In the above-mentioned pediatric formula food, further preferably, the whey and / or concentrated whey may be in liquid and / or powder form, preferably, it may be desalted whey powder or whey protein powder.

[0018] In the above-mentioned pediatric formula food, it is further preferred that the prebiotic is one or a combination of two or more of galacto-oligosaccharides, fructo-oligosaccharides, isomerized lactose and fucyl lactose.

[0019] In the above-mentioned pediatric formula food, it is further preferred that the mineral is one or a combination of two or more of complex minerals, milk mineral salts and calcium carbonate.

[0020] The present invention also provides a method for preparing the above-mentioned pediatric formula food, wherein, when the food is a powdered pediatric formula food and / or a powdered children's reconstituted milk powder, the steps are: proportioning, homogenizing, pasteurizing, spray drying and dry mixing;

[0021] Mix ingredients in proportion to ensure uniform distribution and formulation stability;

[0022] The mixed material is homogenized after filtering and removing impurities, and the homogenization temperature is not less than 50°C and the pressure is not less than 120bar;

[0023] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 40% to 60%;

[0024] The concentrated material is sterilized at above 80°C for 10 to 60 seconds;

[0025] The sterilized material is dried by a spray drying tower (inlet air temperature 150°C ~ 200°C, exhaust air temperature 80°C ~ 120°C, negative pressure -10 ~ -2mmWG, high pressure pump pressure 140 ~ 250bar), and then introduced into a fluidized bed for secondary drying to obtain a powder;

[0026] When the food is liquid milk, the steps are: fresh milk purification, cold storage, proportion mixing and high temperature instant sterilization. Specifically, the fresh milk is filtered through a membrane and purified, then stored at 2-8°C for use, the ingredients are mixed in proportion to ensure uniform distribution and formula stability, and then sterilized at 135-150°C for 2-8s before aseptic filling.

[0027] The "children" referred to in this manual refer to children and adolescents aged between 0 and 18 years old. According to different age groups and growth and development characteristics, "children" can be further divided into the following stages:

[0028] Infancy (0-1 years old): refers to children from birth to 1 year old. During this period, children's cognitive ability, motor ability and language ability are at the initial stage of development, and they usually need to rely heavily on adult care.

[0029] Early childhood (1-3 years old): refers to children aged 1 to 3 years old. Children at this stage begin to develop basic motor skills and language communication skills, but still need a high level of supervision. Preschool and school age (3-12 years old): refers to children aged 3 to 12 years old. Children at this stage have rapid physical and cognitive development, have a certain level of understanding and operation, and can use simple equipment or objects independently under adult supervision.

[0030] Adolescence (12-18 years old): refers to children and adolescents aged 12 to 18. Children at this stage have a high degree of independence, and their physical and cognitive abilities are maturing, but they are still in the process of development, and specific design and use parameters may need to be considered to ensure their safety.

[0031] This definition applies to all parts of this patent involving "children" to ensure that the patented technology, products or methods meet the safety standards and applicability for use by children and adolescents. The design and use parameters of specific products or equipment can be appropriately adjusted according to the characteristics of different age groups to ensure their safety and effectiveness.

[0032] The technical solution of the present invention has the following beneficial technical effects:

[0033] The pediatric formula food provided by the present invention contains a composition of lactoferrin and pyrroloquinoline quinone disodium salt in a specific ratio, which can significantly promote skeletal muscle development, ensure that children can fully absorb and utilize these key nutrients, and significantly improve muscle quality, muscle strength and muscle function. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is the grouping and drug administration of animal experiments.

[0035] Figure 2 The figure shows the body weight change curve of mice in each group.

[0036] Figure 3 The following are the data results of lean meat content in each group of mice.

[0037] Figure 4 The following are the fat content data of each group of mice.

[0038] Figure 5 The skeletal muscle mass and index data results after sampling from each group of mice.

[0039] Figure 6 The maximum muscle strength data of each group of mice.

[0040] Figure 7 Shown are the grid hanging time data results for each group of mice.

[0041] Figure 8 The figures are the exhaustion time data of each group of mice. DETAILED DESCRIPTION

[0042] In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the technical solution of the present invention is now described in detail below, but it should not be construed as limiting the applicable scope of the present invention.

[0043] The present invention provides a composition consisting of lactoferrin and pyrroloquinoline quinone disodium salt. The efficacy experiment of the composition in promoting skeletal muscle development is as follows: Figure 1 Animal experiment grouping and drug administration:

[0044] 1) Animal experiments

[0045] Six-week-old male SPF C57BL / 6 mice, weighing 20±1 g / mouse, were purchased from Speffort. The breeding conditions were room temperature 22±2°C, light and dark cycles of 12 h each, and they were adapted for one week after purchase.

[0046] Experimental drug preparation:

[0047] aD-galactose: D-galactose powder (Sigma, A3134) was accurately weighed and intraperitoneally injected at a dose of 500 mg / kg / day according to the mouse body weight, and dissolved in distilled water. The intraperitoneal injection volume for each mouse was 100 μL, and the solvent concentration was 100 mg / mL.

[0048] b. Lactoferrin: Accurately weigh lactoferrin powder and gavage the mice at a dose of 500 mg / kg / day according to their body weight. Slowly dissolve the powder in distilled water in batches and stir magnetically for 5 minutes at 55°C to fully dissolve it. The gavage volume for each mouse is 100 μL, and the solvent concentration is 100 mg / mL.

[0049] c. Pyrroloquinoline quinone disodium salt (PQQ): Precisely weigh pyrroloquinoline quinone disodium salt (PQQ) powder (Hubei Meiqi Health Technology Co., Ltd., CAS122628-50-6) and gavage the mice at a dose of 20 mg / kg / day according to their body weight. Add the powder into distilled water to fully dissolve it. The gavage volume for each mouse was 100 μL, and the solvent concentration was 4 mg / mL.

[0050] d. Lactoferrin and pyrroloquinoline quinone disodium salt (PQQ) mixed solution: A certain amount of lactoferrin and pyrroloquinoline quinone disodium salt (PQQ) powder (Hubei Meiqi Health Technology Co., Ltd., CAS122628-50-6) were accurately weighed respectively, the weight ratio of lactoferrin to pyrroloquinoline quinone disodium salt (PQQ) powder was 25:1, and it was fully dissolved according to the above dissolution method, and the gavage volume for each mouse was 100 μL.

[0051] Animal Grouping:

[0052] Six-week-old male SPF C57BL / 6 mice were randomly divided into five groups, with six mice in each group, namely the normal control group, sarcopenia model group, lactoferrin group, pyrroloquinoline quinone disodium salt group (PQQ group), and lactoferrin and pyrroloquinoline quinone disodium salt combined intervention group (combined group). The normal control group was intraperitoneally injected and gavaged with normal saline every day, and the other four groups were intraperitoneally injected with D-galactose every day, the sarcopenia model group was gavaged with normal saline every day, the lactoferrin group was gavaged with lactoferrin solution every day, the PQQ group was gavaged with pyrroloquinoline quinone disodium salt solution every day, and the combined group was gavaged with a mixed solution of lactoferrin and pyrroloquinoline quinone disodium salt every day for 8 weeks. Each group of mice was intraperitoneally and gavaged once a day, and the experimental period was 56 days. During the experiment, the mice in each group had free access to food and water, and the mice were weighed regularly every week.

[0053] Test materials:

[0054] After the last oral administration of the mice, the behavioral experiment of mice was carried out immediately the next day. After the test, the skeletal muscles of the tibialis anterior (TA), soleus (SOL), extensor digitorum longus (EDL), gastrocnemius (GAS) and other hind limbs of the mice were taken and weighed. The skeletal muscles of the left leg of the mice were preserved in tissue fixative, and the skeletal muscles of the right leg were quickly frozen in liquid nitrogen and placed in a -80°C refrigerator for use.

[0055] 2) Body composition analysis

[0056] Body composition analysis and imaging

[0057] After the intervention, the body composition of mice was measured using the awake small animal body composition analysis and imaging system (animal fat meter). The mice were weighed before the test and then placed in the instrument after self-check. After the measurement, the physiological parameters such as lean meat content and fat content of the mice in the awake state were obtained. Each mouse was measured 2-3 times.

[0058] 3) Behavioral experiments

[0059] a. Inverted grid suspension experiment

[0060] The Inverted Grid is a 43cm wire mesh consisting of 1mm diameter wires. It is surrounded by a 4cm deep wooden bearing (to prevent the occasional mouse from trying to climb to the other side). Each animal is placed in the center of the grid, then inverted 180° and placed 40cm above the cage pad. A timer is used to record the time the animal is suspended on the wire. If the mouse falls within 10s, the test should be repeated immediately to ensure accuracy. The test is based on the mouse's instinctive fear of falling, so it is best to let it complete this test in an unknown state in a limited number of repetitions.

[0061] b. Grip strength test

[0062] The test was carried out using a rat and mouse grip strength tester (model: ZS-ZL). The basic process is divided into the following steps:

[0063] (1) Install the elastic metal strip onto the sensor and secure it.

[0064] (2) Turn on the sensor and select peak mode. Do not apply a force greater than the sensor's strength tolerance.

[0065] (3) The display sensor is reset to zero.

[0066] (4) Take the mouse out of the cage and grab the middle of the mouse's tail between your thumb and index finger.

[0067] (5) Limb measurement: Place the mouse on the elastic metal bar, and allow the mouse's front and hind paws to touch the elastic metal bar before measurement, keep the torso and the elastic metal bar horizontal, and gently pull the mouse's tail from the top of the elastic metal bar until the mouse can no longer maintain its grip and the metal bar falls off its paws. During the test, the measuring device will record the maximum limb muscle force value (g) and display it on the screen of the instrument. Each mouse will be tested three times in a row.

[0068] c. Treadmill test

[0069] (1) Adaptation stage

[0070] Table 1

[0071]

[0072]

[0073] The test was conducted using a small animal treadmill (model: ZS-PT-IV), and the treadmill parameters during the adaptation phase were set as shown in Table 1. The treadmill stimulation current was set to 0.3 mA, and this gradual training method was used to adapt the animals to the treadmill. This adaptation process lasted 2-3 days, once a day, and each time was about 10 minutes.

[0074] (2) Testing phase

[0075] Table 2

[0076] Speed(m / min) Acceleration time(s) Speed ​​duration (min) Initial Speed 10 5 2 First speed 15 5 3 Secondary speed 20 5 To exhaustion

[0077] The treadmill parameters for the test phase are shown in Table 2. The treadmill stimulation current was set to 0.3 mA. Exhaustion was indicated by the mice stopping running for 10 seconds and then failing to run after 5 seconds of electrical and noise stimulation. The exhaustion time of the mice was recorded. This process was repeated once a day for 2-3 days.

[0078] The present invention has completed animal level verification.

[0079] 4) Experimental results

[0080] 1. Figure 2 is the weight change curve of mice. Figure 2 It can be seen that the body weight of mice in each group showed an upward trend.

[0081] 2. Figure 3 and Figure 4 The data are respectively the lean meat content and fat content of each group of mice. Figure 3 and Figure 4It can be seen that compared with the sarcopenia model group mice, the lean meat content of mice significantly recovered after the intervention of lactoferrin and PQQ alone or in combination, and was close to that of the normal control group; at the same time, the accumulation of fat was delayed. The increase in lean meat content and the decrease in fat content of mice represent an increase in the proportion of their muscle tissue, indicating that the skeletal muscle development and growth of mice have been improved.

[0082] 3. Skeletal muscle index is the criterion for judging muscle atrophy. Figure 5 The skeletal muscle mass and index test results after sampling from each group of mice. Figure 5 It can be seen that the muscle index of the skeletal muscles of the hind limbs of the sarcopenia model group was significantly lower than that of the normal control group mice, indicating that the sarcopenia model group mice had aging muscle atrophy and the experimental model was successful. Figure 5 A in the figure is the test result of gastrocnemius muscle quality. Figure 5 E in it is the gastrocnemius index test result), tibialis anterior (TA) ( Figure 5 B in the figure is the test result of tibialis anterior muscle quality. Figure 5 F is the tibialis anterior muscle index test result), extensor digitorum longus (EDL) ( Figure 5 The C in the figure is the test result of the mass of the extensor digitorum longus muscle. Figure 5 G in it is the result of the test of the extensor digitorum longus index), soleus muscle (SOL) ( Figure 5 D in the figure is the test result of soleus muscle quality. Figure 5 The H in the figure is the soleus muscle index test result) were significantly reduced. After the intervention of lactoferrin and PQQ alone or in combination, the mass and index of the four parts of skeletal muscle were adjusted to varying degrees, and the corresponding skeletal muscle mass and index of the combined group were closer to or even higher than those of the normal control group, indicating that nutritional intervention has a certain improvement effect on the reduction of muscle mass, and the combined effect of lactoferrin and PQQ is more obvious.

[0083] 4. Figure 6 The maximum muscle strength test results of each group of mice. Figure 6 It can be seen that compared with the sarcopenia model group, the maximum muscle strength values ​​of each group of mice were significantly improved after single or combined intervention with lactoferrin and PQQ, and the combined group was significantly higher than the lactoferrin group and PQQ group, indicating that combined intervention can better improve the muscle strength of sarcopenia mice.

[0084] 5. Figure 7 and Figure 8 The following are the grid hanging time test results and exhaustion time test results of each group of mice. Figure 7 , Figure 8It can be seen that compared with the sarcopenia model group, after the intervention of lactoferrin and PQQ alone or in combination, the exhaustion time and the hanging time of the inverted grid in the treadmill test of each group of mice were prolonged, and the combined group was significantly longer than the lactoferrin group and PQQ group, indicating that the muscle endurance and function of mice were better improved after the combined intervention.

[0085] Preparation of pediatric formula food containing composition for promoting skeletal muscle development

[0086] Example 1

[0087] The present embodiment provides a powdered pediatric formula food, wherein the total protein content of the powdered pediatric formula food is 10.5 g / 100 g, the lactoferrin content is 60 mg / 100 g, the pyrroloquinoline quinone disodium salt (PQQ) content is 3 mg / 100 g, the fat content is 27.9 g / 100 g; and the carbohydrate content is 54.6 g / 100 g;

[0088] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0089] 1000 parts of raw milk, 290 parts of desalted whey powder, 230 parts of lactose, 226 parts of edible vegetable blending oil, 40.5 parts of galacto-oligosaccharide, 32 parts of whey protein powder, 17.5 parts of fructo-oligosaccharide, 4 parts of phospholipids, 3.5 parts of complex vitamins and 13 parts of minerals.

[0090] The powdered pediatric formula food of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0091] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0092] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0093] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0094] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0095] The concentrated material was sterilized at 85°C for 15 seconds;

[0096] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0097] After testing, all indicators of the finished product meet the requirements of relevant food standards.

[0098] Example 2

[0099] The present embodiment provides a powdered pediatric formula food, wherein the total protein content of the powdered pediatric formula food is 12 g / 100 g, the lactoferrin content is 175 mg / 100 g, the pyrroloquinoline quinone disodium salt (PQQ) content is 7 mg / 100 g, the fat content is 23 g / 100 g; and the carbohydrate content is 57.6 g / 100 g;

[0100] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0101] 1000 parts of raw milk, 275 parts of lactose, 225 parts of desalted whey powder, 181 parts of edible vegetable blending oil, 130 parts of skimmed milk powder, 12.5 parts of galacto-oligosaccharides, 15 parts of whey protein powder, 10 parts of casein, 5 parts of oligofructose, 4 parts of phospholipids, 3.5 parts of complex vitamins, and 13 parts of minerals.

[0102] The powdered pediatric formula food of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0103] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0104] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0105] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0106] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0107] The concentrated material was sterilized at 85°C for 15 seconds;

[0108] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0109] After testing, all indicators of the finished product meet the requirements of relevant food standards.

[0110] Example 3

[0111] The present embodiment provides a pediatric formula liquid milk, wherein the total protein content in the pediatric formula liquid milk is 13.8 g / 100 g in terms of dry matter content, the lactoferrin content is 360 mg / 100 g, the pyrroloquinoline quinone disodium salt (PQQ) content is 12 mg / 100 g, the fat content is 22 g / 100 g, and the carbohydrate content is 55.7 g / 100 g;

[0112] This embodiment is achieved by compounding the following raw materials in parts by weight, and the raw material composition includes (preparing 1000 parts of dry matter):

[0113] 1000 parts of raw milk, 225 parts of skimmed milk powder, 220 parts of desalted whey powder, 200 parts of lactose, 181 parts of edible vegetable blending oil, 13.5 parts of galacto-oligosaccharides, 9 parts of whey protein powder, 6 parts of oligofructose, 1 part of casein, 4 parts of phospholipids, 3.5 parts of complex vitamins, and 11 parts of minerals.

[0114] The infant formula liquid milk of this embodiment is prepared by the existing process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, high temperature instant sterilization, aseptic filling and sealing to obtain the finished product;

[0115] The specific steps include:

[0116] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0117] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0118] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0119] Subsequently, the homogenized material is sterilized at 135°C for 5 seconds and then aseptically filled.

[0120] After testing, all indicators of the finished product meet the requirements of relevant food standards.

[0121] Example 4

[0122] The present embodiment provides a powdered children's formula milk powder, wherein the powdered children's formula milk powder has a total protein content of 19 g / 100 g, a lactoferrin content of 30 mg / 100 g, a pyrroloquinoline quinone disodium salt (PQQ) content of 1.5 mg / 100 g, a fat content of 18 g / 100 g, and a carbohydrate content of 55 g / 100 g;

[0123] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0124] 4400 parts of raw cow's milk, 400 parts of desalted whey powder, 25 parts of whey protein powder, 15 parts of galacto-oligosaccharides, 15 parts of calcium carbonate, 7 parts of milk mineral salts, 6 parts of isomerized lactose, 3 parts of complex vitamins, 2 parts of phospholipids, 1 part of complex minerals, and 1 part of choline.

[0125] The powdered children's formula milk powder of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0126] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0127] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0128] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0129] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0130] The concentrated material was sterilized at 85°C for 15 seconds;

[0131] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0132] Upon testing, it was found that various indicators of the finished product met the food standard requirements for children's formula milk powder.

[0133] Example 5

[0134] The present embodiment provides a powdered children's formula milk powder, wherein the powdered children's formula milk powder has a total protein content of 20 g / 100 g, a lactoferrin content of 60 mg / 100 g, a pyrroloquinoline quinone disodium salt (PQQ) content of 2.4 mg / 100 g, a fat content of 13.5 g / 100 g, and a carbohydrate content of 58.5 g / 100 g;

[0135] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0136] 3400 parts of raw milk, 275 parts of skimmed milk powder, 200 parts of lactose, 100 parts of desalinated whey powder, 12 parts of calcium carbonate, 5 parts of milk mineral salts, 2.5 parts of complex vitamins, 2 parts of phospholipids, 1 part of complex minerals, and 1 part of choline.

[0137] The powdered children's formula milk powder of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0138] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0139] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0140] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0141] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0142] The concentrated material was sterilized at 85°C for 15 seconds;

[0143] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0144] Upon testing, it was found that various indicators of the finished product met the food standard requirements for children's formula milk powder.

[0145] Example 6

[0146] The present embodiment provides a powdered children's formula milk powder, wherein the powdered children's formula milk powder has a total protein content of 20 g / 100 g, a lactoferrin content of 90 mg / 100 g, a pyrroloquinoline quinone disodium salt (PQQ) content of 3 mg / 100 g, a fat content of 13.5 g / 100 g, and a carbohydrate content of 58.5 g / 100 g;

[0147] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0148] 3100 parts of raw milk, 360 parts of skimmed milk powder, 230 parts of lactose, 15 parts of galacto-oligosaccharides, 15 parts of calcium carbonate, 6 parts of isomerized lactose liquid, 5 parts of milk mineral salts, 2.5 parts of complex vitamins, 2 parts of phospholipids, 1 part of complex minerals, and 1 part of choline.

[0149] The powdered children's formula milk powder of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0150] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0151] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0152] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0153] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0154] The concentrated material was sterilized at 85°C for 15 seconds;

[0155] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

Claims

1. A pediatric formula food comprising a composition of lactoferrin and pyrroloquinoline quinone disodium salt, wherein the weight ratio of lactoferrin to pyrroloquinoline quinone disodium salt is 20:1-30:

1.

2. The pediatric formula food according to claim 1, wherein: The weight ratio of lactoferrin to pyrroloquinoline quinone disodium salt is 22:1-28:1; preferably, the weight ratio of lactoferrin to pyrroloquinoline quinone disodium salt is 25:

1.

3. The pediatric formula food according to claim 1, wherein: Based on the mass of the pediatric formula food, the added amount of lactoferrin is 30-360 mg / 100 g, and the added amount of pyrroloquinoline quinone disodium salt is 1.5-12 mg / 100 g.

4. The pediatric formula food according to claim 1, wherein: The purity of the pyrroloquinoline quinone disodium salt is ≥98.0 g / 100 g, calculated on a dry basis.

5. The pediatric formula food according to any one of claims 1 to 4, wherein: The pediatric formula food is powdered pediatric formula food, powdered children's formula milk powder or pediatric formula liquid milk.

6. The pediatric formula food according to claim 5, wherein: Based on the preparation of 1000 parts by weight of the powdered pediatric formula food, the raw materials of the powdered pediatric formula food include: 0-7000 parts by weight of raw cow's milk, 0-600 parts by weight of desalted whey powder, 0-500 parts by weight of lactose, 0-500 parts by weight of skim milk powder, 0-400 parts by weight of edible vegetable blending oil, 0-100 parts by weight of prebiotics, 0-120 parts by weight of whey protein powder, 0-20 parts by weight of phospholipids, 0-20 parts by weight of vitamins, 0-40 parts by weight of casein, and 0-30 parts by weight of minerals; Based on the preparation of 1000 parts by weight of the powdered children's formula milk powder, the raw material composition of the powdered children's formula milk powder includes: 0-7000 parts by weight of raw cow's milk, 0-500 parts by weight of skim milk powder, 0-600 parts by weight of desalted whey powder, 0-120 parts by weight of whey protein powder, 0-500 parts by weight of lactose, 0-50 parts by weight of prebiotics, 0-5 parts by weight of choline, 0-10 parts by weight of phospholipids, 0-20 parts by weight of vitamins, and 0-30 parts by weight of minerals; Based on the preparation of 1000 parts by weight of the pediatric formula liquid milk, the raw material composition of the pediatric formula liquid milk includes: 0-7000 parts by weight of raw cow's milk, 0-500 parts by weight of skim milk powder, 0-500 parts by weight of desalted whey powder, 0-500 parts by weight of lactose, 0-400 parts by weight of edible vegetable blending oil, 0-100 parts by weight of prebiotics, 0-120 parts by weight of whey protein powder, 0-10 parts by weight of phospholipids, 0-40 parts by weight of casein, 0-20 parts by weight of vitamins, and 0-30 parts by weight of minerals.

7. The pediatric formula food according to claim 6, wherein: The raw milk is partially skimmed milk.

8. The pediatric formula food according to claim 6, wherein: The prebiotics are one or a combination of two or more of galacto-oligosaccharides, fructo-oligosaccharides, isomerized lactose and fucyl lactose.

9. The pediatric formula food according to claim 6, wherein: The minerals are one or a combination of two or more of complex minerals, milk mineral salts and calcium carbonate.

10. Use of a composition in the preparation of a product for promoting bone and development, wherein: The composition contains lactoferrin and pyrroloquinoline quinone disodium salt, and the weight ratio of lactoferrin to pyrroloquinoline quinone disodium salt is 20:1-30:1; preferably, the product is a pediatric formula food.

Images